Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
32 "Woo Je Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Drug/Regimen
Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
Received February 3, 2023  Accepted July 10, 2023  Published online February 2, 2024  
DOI: https://doi.org/10.4093/dmj.2023.0030    [Epub ahead of print]
  • 482 View
  • 43 Download
AbstractAbstract PDFSupplementary MaterialPubReader   
Background
To investigate the real-world safety and effectiveness of dulaglutide in Korean adults with type 2 diabetes mellitus (T2DM).
Methods
This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data. Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled. The primary objective was to report the frequency and proportion of adverse and serious adverse events that occurred. The secondary objective was to monitor the effectiveness of dulaglutide at 12 and 24 weeks by evaluating changes in glycosylated hemoglobin (HbA1c ), fasting plasma glucose, and body weight.
Results
Data were collected from 3,067 subjects, and 3,022 subjects who received ≥1 dose (of any strength) of dulaglutide were included in the safety analysis set (53% female, mean age 56 years; diabetes duration 11.2 years, mean HbA1c 8.8%). The number of adverse events reported was 819; of these, 68 (8.3%) were serious adverse events. One death was reported. Adverse events were mostly mild in severity; 60.81% of adverse events were considered related to dulaglutide. This study was completed by 72.73% (2,198/3,022) of subjects. At 12/24 weeks there were significant (P<0.0001) reductions from baseline in least-squares mean HbA1c (0.96%/0.95%), fasting blood glucose (26.24/24.43 mg/dL), and body weight (0.75/1.21 kg).
Conclusion
Dulaglutide was generally well tolerated and effective in real-world Korean individuals with T2DM. The results from this study contribute to the body of evidence for dulaglutide use in this population.
Metabolic Risk/Epidemiology
Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography
Hwi Seung Kim, Jiwoo Lee, Eun Hee Kim, Min Jung Lee, In Young Bae, Woo Je Lee, Joong-Yeol Park, Hong-Kyu Kim, Chang Hee Jung
Diabetes Metab J. 2023;47(1):104-117.   Published online January 26, 2023
DOI: https://doi.org/10.4093/dmj.2022.0081
  • 3,116 View
  • 175 Download
  • 7 Web of Science
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The association of myosteatosis measured using visual muscular quality map in computed tomography (CT) with nonalcoholic fatty liver disease (NAFLD), its severity, and fibrosis was analyzed in a large population.
Methods
Subjects (n=13,452) with abdominal CT between 2012 and 2013 were measured total abdominal muscle area (TAMA) at L3 level. TAMA was segmented into intramuscular adipose tissue and skeletal muscle area (SMA), which was further classified into normal attenuation muscle area (NAMA) and low attenuation muscle area (LAMA). The following variables were adopted as indicators of myosteatosis: SMA/body mass index (BMI), NAMA/BMI, NAMA/TAMA, and LAMA/BMI. NAFLD and its severity were assessed by ultrasonography, and liver fibrosis was measured by calculating the NAFLD fibrosis score (NFS) and fibrosis-4 index (FIB-4) scores.
Results
According to multiple logistic regression analyses, as quartiles of SMA/BMI, NAMA/BMI, and NAMA/TAMA increased, the odds ratios (ORs) for NAFLD decreased in each sex (P for trend <0.001 for all). The ORs of moderate/severe NAFLD were significantly higher in the Q1 group than in the Q4 group for SMA/BMI, NAMA/BMI, and NAMA/TAMA in men. The ORs of intermediate/high liver fibrosis scores assessed by NFS and FIB-4 scores increased linearly with decreasing quartiles for SMA/BMI, NAMA/BMI, and NAMA/TAMA in each sex (P for trend <0.001 for all). Conversely, the risk for NAFLD and fibrosis were positively associated with LAMA/BMI quartiles in each sex (P for trend <0.001 for all).
Conclusion
A higher proportion of good quality muscle was associated with lower risks of NAFLD and fibrosis.

Citations

Citations to this article as recorded by  
  • Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)
    Hwi Seung Kim, Hong-Kyu Kim, Chang Hee Jung
    Diabetes & Metabolism Journal.2023; 47(2): 304.     CrossRef
  • Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)
    Eun Roh
    Diabetes & Metabolism Journal.2023; 47(2): 301.     CrossRef
  • Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?
    Giovanni Tarantino, Gaia Sinatti, Vincenzo Citro, Silvano Santini, Clara Balsano
    Internal and Emergency Medicine.2023; 18(7): 1887.     CrossRef
  • Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
    Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
    Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
  • Current view of the surgical anatomy of the anterolateral abdominal wall muscles and their aponeuroses
    A.V. Pavlov, A.S. Baranova, A.V. Fedoseyev, A.I. Vvedensky, G.S. Lazutina, N.V. Ovchinnikova, I.V. Bakharev
    Operativnaya khirurgiya i klinicheskaya anatomiya (Pirogovskii nauchnyi zhurnal).2023; 7(3): 44.     CrossRef
  • Muscle Fat Content Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Chinese Adults
    W. Guo, X. Zhao, D. Cheng, X. Liang, M. Miao, X. Li, J. Lu, N. Xu, Shuang Hu, Qun Zhang
    The Journal of nutrition, health and aging.2023; 27(11): 960.     CrossRef
Response
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Hwi Seung Kim, Woo Je Lee
Diabetes Metab J. 2022;46(4):665-666.   Published online July 27, 2022
DOI: https://doi.org/10.4093/dmj.2022.0166
[Original]
  • 2,321 View
  • 130 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
    Maria Elena Lunati, Vincenzo Cimino, Davide Bernasconi, Alessandra Gandolfi, Paola Silvia Morpurgo, Camilla Tinari, Elisa Lazzaroni, Laura Baruffaldi, Milena Muratori, Laura Montefusco, Ida Pastore, Antonio Rossi, Ivano Giuseppe Franzetti, Fabrizio Murato
    Pharmacological Research.2024; 199: 107040.     CrossRef
Short Communication
Technology/Device
A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus
Jiyun Park, Nammi Park, Sangjin Han, You-Bin Lee, Gyuri Kim, Sang-Man Jin, Woo Je Lee, Jae Hyeon Kim
Diabetes Metab J. 2022;46(6):941-947.   Published online March 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0299
  • 5,064 View
  • 268 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
This study evaluated the safety and efficacy of tubeless patch pump called EOPatch in patients with well-controlled type 1 diabetes mellitus (T1DM). This 4-week, two-center, open-label, single-arm study enrolled 10 adult patients diagnosed with T1DM with glycosylated hemoglobin less than 7.5%. The co-primary end points were patch pump usage time for one attachment and number of serious adverse events related to the patch pump. The secondary end points were total amount of insulin injected per patch and changes in glycemic parameters including continuous glucose monitoring data compared to those at study entry. The median usage time per patch was 84.00 hours (interquartile range, 64.50 to 92.50). Serious adverse events did not occur during the trial. Four weeks later, time in range 70 to 180 mg/dL was significantly improved (70.71%±17.14 % vs. 82.96%±9.14%, P=0.01). The times spent below range (<54 mg/dL) and above range (>180 mg/dL) also improved (All P<0.05). Four-week treatment with a tubeless patch pump was safe and led to clinical improvement in glycemic control.

Citations

Citations to this article as recorded by  
  • Multilayer track‐etched membrane‐based electroosmotic pump for drug delivery
    Qian Yang, Zebo Zhang, Junshu Lin, Boyu Zhu, Rongying Yu, Xinru Li, Bin Su, Bo Zhao
    ELECTROPHORESIS.2024; 45(5-6): 433.     CrossRef
  • A true continuous healthcare system for type 1 diabetes
    Jiyong Kim, Salman Khan, Eun Kyu Kim, Hye-Jun Kil, Bo Min Kang, Hyo Geon Lee, Jin-Woo Park, Jun Young Yoon, Woochul Kim
    Nano Energy.2023; 113: 108553.     CrossRef
Original Article
Metabolic Risk/Epidemiology
Sex Differences of Visceral Fat Area and Visceral-to-Subcutaneous Fat Ratio for the Risk of Incident Type 2 Diabetes Mellitus
Eun Hee Kim, Hong-Kyu Kim, Min Jung Lee, Sung-Jin Bae, Jaewon Choe, Chang Hee Jung, Chul-Hee Kim, Joong-Yeol Park, Woo Je Lee
Diabetes Metab J. 2022;46(3):486-498.   Published online November 18, 2021
DOI: https://doi.org/10.4093/dmj.2021.0095
  • 8,968 View
  • 359 Download
  • 17 Web of Science
  • 20 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study aimed to determine the optimal cut-off values of visceral fat area (VFA) and visceral-to-subcutaneous fat ratio (VSR) for predicting incident type 2 diabetes mellitus (T2DM).
Methods
A total of 10,882 individuals (6,835 men; 4,047 women) free of T2DM at baseline aged between 30 and 79 years who underwent abdominal computed tomography scan between 2012 and 2013 as a part of routine health check-ups were included and followed. VFA, subcutaneous fat area, and VSR on L3 vertebral level were measured at baseline.
Results
During a median follow-up of 4.8 years, 730 (8.1% for men; 4.3% for women) incident cases of T2DM were identified. Receiver operating characteristic curve analysis showed that the optimal cut-off values of VFA and VSR for predicting incident T2DM were 130.03 cm2 and 1.08 in men, respectively, and 85.7 cm2 and 0.48 in women, respectively. Regardless of sex, higher VFA and VSR were significantly associated with a higher risk of incident T2DM. Compared with the lowest quartiles of VFA and VSR, the highest quartiles had adjusted odds ratios of 2.62 (95% confidence interval [CI], 1.73 to 3.97) and 1.55 (95% CI, 1.14 to 2.11) in men, respectively, and 32.49 (95% CI, 7.42 to 142.02) and 11.07 (95% CI, 3.89 to 31.50) in women, respectively.
Conclusion
Higher VFA and VSR at baseline were independent risk factors for the development of T2DM. Sex-specific reference values for visceral fat obesity (VFA ≥130 cm2 or VSR ≥1.0 in men; VFA ≥85 cm2 or VSR ≥0.5 in women) are proposed for the prediction of incident T2DM.

Citations

Citations to this article as recorded by  
  • Severity of adipose tissue dysfunction is associated with progression of pre-diabetes to type 2 diabetes: the Tehran Lipid and Glucose Study
    Mohammad Jalali, Zahra Bahadoran, Parvin Mirmiran, Fereidoun Azizi, Farhad Hosseinpanah
    BMC Public Health.2024;[Epub]     CrossRef
  • Should insulin resistance (HOMA-IR), insulin secretion (HOMA-β), and visceral fat area be considered for improving the performance of diabetes risk prediction models
    Huan Hu, Tohru Nakagawa, Toru Honda, Shuichiro Yamamoto, Tetsuya Mizoue
    BMJ Open Diabetes Research & Care.2024; 12(1): e003680.     CrossRef
  • Adipose organ dysfunction and type 2 diabetes: Role of nitric oxide
    Zahra Bahadoran, Parvin Mirmiran, Asghar Ghasemi
    Biochemical Pharmacology.2024; 221: 116043.     CrossRef
  • Prediction of high visceral adipose tissue for sex‐specific community residents in Taiwan
    Yu‐Hsuan Chang, Chin‐Sung Chang, Chieh‐Yu Liu, Yin‐Fan Chang, Shiow‐Ching Shun
    Nursing & Health Sciences.2024;[Epub]     CrossRef
  • Body Composition and Metabolic Dysfunction Really Matter for the Achievement of Better Outcomes in High-Grade Serous Ovarian Cancer
    Mauricio A. Cuello, Fernán Gómez, Ignacio Wichmann, Felipe Suárez, Sumie Kato, Elisa Orlandini, Jorge Brañes, Carolina Ibañez
    Cancers.2023; 15(4): 1156.     CrossRef
  • MEDICINAL BIOMAGNETISM FOR THE TREATMENT OF OBESITY
    Ana Vergínia Campagnollo Bueno, Michelli Gonçalves Seneda, Ângela Mara Rambo, Ana Clara Campagnolo Gonçalves Toledo, Caroline Cabral de Azevedo, Adriane Viapiana Bossa
    Health and Society.2023; 3(01): 411.     CrossRef
  • Cumulative exposure to metabolic syndrome in a national population-based cohort of young adults and sex-specific risk for type 2 diabetes
    Min-Kyung Lee, Jae-Hyuk Lee, Seo Young Sohn, Jiyeon Ahn, Oak-Kee Hong, Mee-Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Kyungdo Han, Hyuk-Sang Kwon
    Diabetology & Metabolic Syndrome.2023;[Epub]     CrossRef
  • The correlation between visceral fat/subcutaneous fat area ratio and monocyte/high-density lipoprotein ratio in patients with type 2 diabetes mellitus and albuminuria
    Haiyan Lin, Jun Zhu, Chen Zheng, Xiaoming Xu, Shandong Ye
    Journal of Diabetes and its Complications.2023; 37(11): 108521.     CrossRef
  • Effects of the abdominal fat distribution on the relationship between exposure to air pollutants and thyroid hormones among Korean adult males
    Hyun-Jin Kim, Byungmi Kim, Seyoung Kim, Hyuktae Kwon, Jae Moon Yun, Belong Cho, Jin-Ho Park
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
    Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
    Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
  • Visceral adipose tissue reference data computed for GE HealthCare DXA from the National Health and Nutrition Examination Survey data set
    Jonathan P. Bennett, Brandon K. Quon, Bo Fan, En Liu, Leila Kazemi, Rosa C. Villegas‐Valle, Raj Ahgun, Xian‐pin Wu, Hou‐De Zhou, Ying Lu, John A. Shepherd
    Obesity.2023; 31(12): 2947.     CrossRef
  • Comparison of bioelectrical body and visceral fat indices and anthropometric measures in relation to type 2 diabetes by sex among Chinese adults, a cross-sectional study
    Jiangshan He, Binbin Zhang, Yaqi Fan, Yuxue Wang, Mianzhi Zhang, Chunjun Li, Li Zhang, Pei Guo, Minying Zhang
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • The predictive significance of lipid accumulation products for future diabetes in a non-diabetic population from a gender perspective: an analysis using time-dependent receiver operating characteristics
    Jiajun Qiu, Maobin Kuang, Yang Zou, Ruijuan Yang, Qing Shangguan, Dingyang Liu, Guotai Sheng, Wei Wang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
    Ren Jie Phang, Rebecca H. Ritchie, Derek J. Hausenloy, Jarmon G. Lees, Shiang Y. Lim
    Cardiovascular Research.2022;[Epub]     CrossRef
  • Implication of Sex Differences in Visceral Fat for the Assessment of Incidence Risk of Type 2 Diabetes Mellitus
    Sang Hyeon Ju, Hyon-Seung Yi
    Diabetes & Metabolism Journal.2022; 46(3): 414.     CrossRef
  • Visceral fat area and body fat percentage measured by bioelectrical impedance analysis correlate with glycometabolism
    Shuying Li, Shaoping Li, Jie Ding, Weihong Zhou
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • The Demographic Specific Abdominal Fat Composition and Distribution Trends in US Adults from 2011 to 2018
    Furong Xu, Jacob E. Earp, Bryan J. Blissmer, Ingrid E. Lofgren, Matthew J. Delmonico, Geoffrey W. Greene
    International Journal of Environmental Research and Public Health.2022; 19(19): 12103.     CrossRef
  • Visceral Obesity Is a More Important Factor for Colorectal Adenomas than Skeletal Muscle or Body Fat
    Ji Yeon Seo, Yoo Min Han, Su Jin Chung, Seon Hee Lim, Jung Ho Bae, Goh Eun Chung
    Cancers.2022; 14(21): 5256.     CrossRef
  • Recent Advances in Visceral Obesity and Related Diseases
    佳佳 魏
    Advances in Clinical Medicine.2022; 12(12): 11686.     CrossRef
  • Gender differences in the ideal cutoffs of visceral fat area for predicting MAFLD in China
    Pingping Yu, Huachao Yang, Xiaoya Qi, Ruixue Bai, Shouqin Zhang, Jianping Gong, Ying Mei, Peng Hu
    Lipids in Health and Disease.2022;[Epub]     CrossRef
Short Communications
Drug/Regimen
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Hwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Diabetes Metab J. 2022;46(4):658-662.   Published online November 8, 2021
DOI: https://doi.org/10.4093/dmj.2021.0232
  • 65,535 View
  • 387 Download
  • 7 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are novel anti-diabetic drugs whose glucose-lowering effect and cardiovascular and renal benefits were evidenced in clinical trials. We investigated the real-world efficacy and safety of the combination of SGLT2i and GLP-1RA in patients with type 2 diabetes mellitus in Korea. The medical records of 104 patients who maintained the combination for at least 1 year were retrospectively reviewed. The change in glycosylated hemoglobin (HbA1c) after 6 months and 1 year of treatment was evaluated. The mean age was 51 years, and 41% were female. The mean baseline HbA1c, body mass index, and duration of diabetes were 9.0%, 28.8 kg/m2, and 11.7 years, respectively. Compared with baseline, the HbA1c decreased by 1.5% (95% confidence interval [CI], 1.27 to 1.74; P<0.001) after 6 months and by 1.4% (95% CI, 1.19 to 1.70; P<0.001) after 1 year. Over 1 year, the bodyweight change was −2.8 kg (95% CI, −4.21 to −1.47; P<0.001). The combination of SGLT2i and GLP-1RA is effective and tolerable in type 2 diabetes mellitus patients in real-world practice.

Citations

Citations to this article as recorded by  
  • Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
    Aftab Ahmad, Hani Sabbour
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Hormonal Gut–Brain Signaling for the Treatment of Obesity
    Eun Roh, Kyung Mook Choi
    International Journal of Molecular Sciences.2023; 24(4): 3384.     CrossRef
  • All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
    David R. Riley, Hani Essa, Philip Austin, Frank Preston, Isatu Kargbo, Gema Hernández Ibarburu, Ramandeep Ghuman, Daniel J. Cuthbertson, Gregory Y. H. Lip, Uazman Alam
    Diabetes, Obesity and Metabolism.2023; 25(10): 2897.     CrossRef
  • The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Chen Li, Jie Luo, Mingyan Jiang, Keke Wang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
    Hwi Seung Kim, Woo Je Lee
    Diabetes & Metabolism Journal.2022; 46(4): 665.     CrossRef
  • Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
    Tomoyuki Kawada
    Diabetes & Metabolism Journal.2022; 46(4): 663.     CrossRef
  • Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
    Hwi Seung Kim, Yun Kyung Cho, Myung Jin Kim, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
Drug/Regimen
Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
Hwi Seung Kim, Jiwoo Lee, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Diabetes Metab J. 2021;45(6):948-953.   Published online February 5, 2021
DOI: https://doi.org/10.4093/dmj.2020.0180
  • 5,683 View
  • 231 Download
  • 5 Web of Science
  • 6 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Dulaglutide, a weekly injectable glucagon-like peptide-1 receptor agonist, has demonstrated effectiveness when combined with basal insulin. We examined whether the efficacy of dulaglutide is comparable to that of prandial insulin in kidney transplant (KT) recipients with type 2 diabetes mellitus (T2DM) undergoing multiple daily insulin injection (MDI) therapy. Thirty-seven patients, who switched from MDI therapy to basal insulin and dulaglutide, were retrospectively analyzed. Changes in glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) levels, body weight, and basal insulin dose were evaluated over 6 months. Dulaglutide was comparable to three injections of prandial insulin in terms of glycemic control (HbA1c 7.1% vs. 7.0%; 95% confidence interval [CI], –0.53 to 0.28; P=0.53). The basal insulin and dulaglutide combination resulted in a reduction in FPG levels by 9.7 mg/dL (95% CI, 2.09 to 41.54; P=0.03), in body weight by 4.9 kg (95% CI, 2.87 to 6.98; P<0.001), and in basal insulin dose by 9.52 IU (95% CI, 5.80 to 3.23; P<0.001). Once-weekly dulaglutide may be an effective alternative for thrice-daily prandial insulin in KT recipients with T2DM currently receiving MDI therapy.

Citations

Citations to this article as recorded by  
  • Diabetic Kidney Disease in Post-Kidney Transplant Patients
    Ngoc-Yen T. Pham, Diego Cruz, Luis Madera-Marin, Raja Ravender, Pablo Garcia
    Journal of Clinical Medicine.2024; 13(3): 793.     CrossRef
  • Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis
    Pajaree Krisanapan, Supawadee Suppadungsuk, Kanokporn Sanpawithayakul, Charat Thongprayoon, Pattharawin Pattharanitima, Supawit Tangpanithandee, Michael A Mao, Jing Miao, Wisit Cheungpasitporn
    Clinical Kidney Journal.2024;[Epub]     CrossRef
  • Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post‐transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation
    S. Elise Lawrence, Mary Moss Chandran, Jeong M. Park, Helen Sweiss, Thomas Jensen, Palak Choksi, Barrett Crowther
    Clinical Transplantation.2023;[Epub]     CrossRef
  • Novel Drugs for the Management of Diabetes Kidney Transplant Patients: A Literature Review
    Nancy Daniela Valencia-Morales, Beatriz Rodríguez-Cubillo, Rómulo Katsu Loayza-López, Maria Ángeles Moreno de la Higuera, Ana Isabel Sánchez-Fructuoso
    Life.2023; 13(6): 1265.     CrossRef
  • Uso de los agonistas del receptor del péptido similar al glucagón tipo 1 en pacientes trasplantados renales
    Luis Alberto Vigara, Florentino Villanego, Cristhian Orellana, Myriam Eady, María Gabriela Sánchez, Marta Alonso, María Belén García, José Manuel Amaro, Teresa García, Auxiliadora Mazuecos
    Nefrología.2023;[Epub]     CrossRef
  • Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
    Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
Original Articles
Type 1 Diabetes
Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus
Jong Ha Baek, Woo Je Lee, Byung-Wan Lee, Soo Kyoung Kim, Gyuri Kim, Sang-Man Jin, Jae Hyeon Kim
Diabetes Metab J. 2021;45(1):46-54.   Published online July 10, 2020
DOI: https://doi.org/10.4093/dmj.2019.0134
  • 6,690 View
  • 229 Download
  • 10 Web of Science
  • 10 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

The aim of this study was to evaluate characteristics and risk of diabetic complications according to age at diagnosis among young adults with type 1 diabetes mellitus (T1DM).

Methods

A total of 255 T1DM patients aged less than 40 years were included. Patients were categorized into three groups (<20, 20 to 29, and 30 to 40 years) according to age at diagnosis. Diabetic nephropathy (DN) was defined when spot urine-albumin creatinine ratio was 300 mg/g or more and/or estimated glomerular filtration ratio (eGFR) level was 60 mL/min/1.73 m2 or less.

Results

Median age at diagnosis was 25 years and disease duration was 14 years. Individuals diagnosed with T1DM at childhood/adolescent (age <20 years) had lower stimulated C-peptide levels. They received more intensive insulin treatment with higher total daily insulin doses compared to older onset groups. The prevalence of DN was higher in the childhood/adolescent-onset group than in older onset groups (25.3% vs. 15.3% vs. 9.6%, P=0.022). The eGFR was inversely associated with disease duration whilst the degree of decrease was more prominent in the childhood/adolescent-onset group than in the later onset group (aged 30 to 40 years; P<0.001). Childhood/adolescent-onset group was independently associated with the risk of DN compared to the older onset group (aged 30 to 40 years; odds ratio, 3.47; 95% confidence interval, 1.45 to 8.33; P=0.005).

Conclusion

In individuals with childhood/adolescent-onset T1DM, the reduction in renal function is more prominent with disease duration. Early age-onset T1DM is an independent risk of DN.

Citations

Citations to this article as recorded by  
  • Age at onset of type 1 diabetes between puberty and 30 years old is associated with increased diabetic nephropathy risk
    Yen-Bo Lin, Wayne Huey-Herng Sheu, Su-Huey Lo, Yen-Po Yeh, Chien-Ning Huang, Chii-Min Hwu, Chang-Hsun Hsieh, Horng-Yi Ou, Lee-Ming Chuang, Jung-Fu Chen, Yu-Cheng Chen, Yun-Hsing Peng, Szu-Tah Chen, Shang-Ren Hsu, Yi-Ling Hsieh, Chih-Hsun Chu, Chieg-Hsiang
    Scientific Reports.2024;[Epub]     CrossRef
  • Targeted mapping and utilization of the perihepatic surface for therapeutic beta cell replacement and retrieval in diabetic non-human primates
    David J. Leishman, Scott H. Oppler, Laura L. Hocum Stone, Timothy D. O’Brien, Sabarinathan Ramachandran, Bradley J. Willenberg, Andrew B. Adams, Bernhard J. Hering, Melanie L. Graham
    Frontiers in Transplantation.2024;[Epub]     CrossRef
  • Network-based identification and prioritization of key transcriptional factors of diabetic kidney disease
    Ikhlak Ahmed, Mubarak Ziab, Sahar Da’as, Waseem Hasan, Sujitha P. Jeya, Elbay Aliyev, Sabah Nisar, Ajaz A. Bhat, Khalid Adnan Fakhro, Ammira S. Alshabeeb Akil
    Computational and Structural Biotechnology Journal.2023; 21: 716.     CrossRef
  • Comparison of diabetes distress and depression screening results of emerging adults with type 1 diabetes onset at different ages: findings from the German early-onset T1D study and the German Diabetes Study (GDS)
    Anna Stahl-Pehe, Christina Bächle, Kálmán Bódis, Oana-Patricia Zaharia, Karin Lange, Reinhard W. Holl, Michael Roden, Joachim Rosenbauer, M. Roden, H. Al-Hasani, B Belgardt, GJ. Bönhof, V Burkart, A. E. Buyken, G. Geerling, C. Herder, A. Icks, K. Jandelei
    Diabetology & Metabolic Syndrome.2023;[Epub]     CrossRef
  • Hemoperfusion and functional state of the macula after simultaneous pancreas and kidney transplantation
    IV Vorobyeva, EV Bulava, LK Moshetova, AV Pinchuk
    Bulletin of Russian State Medical University.2022;[Epub]     CrossRef
  • Sigesbeckia orientalis Extract Ameliorates the Experimental Diabetic Nephropathy by Downregulating the Inflammatory and Oxidative Stress Signaling Pathways
    Chung-Ming Chen, Jer-Yiing Houng, Tsui-Ling Ko, Shu-Hui Juan, Hsiu-Chu Chou, Xing Li
    Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1.     CrossRef
  • Impact of low-protein diet on cardiovascular risk factors and kidney function in diabetic nephropathy: A systematic review and meta-analysis of randomized-controlled trials
    Mohammad Hassan Sohouli, Parvin Mirmiran, Shaikh Sanjid Seraj, Emad Kutbi, Hadil Ali Mohammed Alkahmous, Faisal Almuqayyid, Omar Ahnaf Arafah, Abdul Rahman Riad Barakeh, Ahmed Abu-Zaid
    Diabetes Research and Clinical Practice.2022; 191: 110068.     CrossRef
  • Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus (Diabetes Metab J 2021;45:46-54)
    Jong Ha Baek, Jae Hyeon Kim
    Diabetes & Metabolism Journal.2021; 45(2): 281.     CrossRef
  • Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus (Diabetes Metab J 2021;45:46-54)
    Ye Seul Yang, Tae Seo Sohn
    Diabetes & Metabolism Journal.2021; 45(2): 277.     CrossRef
  • Role of magnetic resonance diffusion weighted imaging in diagnosis of diabetic nephropathy in children living with type 1 diabetes mellitus
    Eman Nabil Wahba, Ashraf Elsharkawy, Mohammad Hosny Awad, Ashraf Abdel Rahman, Amr Sarhan
    Journal of Pediatric Endocrinology and Metabolism.2021; 34(12): 1585.     CrossRef
Cardiovascular Risk/Epidemiology
Impact of Diabetes Control on Subclinical Atherosclerosis: Analysis from Coronary Computed Tomographic Angiography Registry
Gyung-Min Park, Chang Hoon Lee, Seung-Whan Lee, Sung-Cheol Yun, Young-Hak Kim, Yong-Giun Kim, Ki-Bum Won, Soe Hee Ann, Shin-Jae Kim, Dong Hyun Yang, Joon-Won Kang, Tae-Hwan Lim, Eun Hee Koh, Woo Je Lee, Min-Seon Kim, Joong-Yeol Park, Hong-Kyu Kim, Jaewon Choe, Sang-Gon Lee
Diabetes Metab J. 2020;44(3):470-479.   Published online November 22, 2019
DOI: https://doi.org/10.4093/dmj.2019.0073
  • 8,577 View
  • 69 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

There are limited data on the impact of diabetes control on the risk of subclinical coronary atherosclerosis.

Methods

We analyzed 6,434 consecutive asymptomatic individuals without previous history of coronary artery disease who underwent coronary computed tomographic angiography (CCTA) (mean age, 53.7±7.6 years and 4,694 men [73.0%]). The degree and extent of subclinical coronary atherosclerosis were assessed by CCTA, and ≥50% diameter stenosis was defined as significant. A cardiac event was defined as a composite of all-cause death, myocardial infarction, unstable angina, or coronary revascularization. Study participants were categorized as normal (n=5,319), controlled diabetes (glycosylated hemoglobin [HbA1c] <7%, n=747), or uncontrolled diabetes (HbA1c ≥7%, n=368), respectively.

Results

Compared with normal individuals, there were no statistically significant differences in the risk of for any atherosclerotic plaque (odds ratio [OR], 1.16; 95% confidence interval [CI], 0.98 to 1.38; P=0.086) and significant coronary artery stenosis (OR, 1.08; 95% CI, 0.82 to 1.42; P=0.583) in controlled diabetic individuals. In contrast, uncontrolled diabetic individuals had consistently higher risks of any atherosclerotic plaque (OR, 2.16; 95% CI, 1.70 to 2.75; P<0.001) and significant coronary artery stenosis (OR, 3.34; 95% CI, 2.52 to 4.43; P<0.001) than normal individuals. During a follow-up of median 5.4 years, there was no significant difference in cardiac events between normal and controlled diabetic individuals (P=0.365). However, uncontrolled diabetes was associated with an increased risk of cardiac events compared with normal individuals (P<0.001) and controlled diabetic individuals (P=0.023).

Conclusion

Asymptomatic uncontrolled diabetes was associated with significant subclinical coronary atherosclerosis with subsequent high risk for cardiac events.

Citations

Citations to this article as recorded by  
  • Carotid Ultrasound Abnormalities of People Living With HIV in Kunming, China: Multiple Correspondence Analysis Approach to Identify Influencing Factors
    Shuishui Pan, Haiyan Fu, Zhiqiong Ai, Chongxi Li, Jinsong Bai
    International Journal of STD & AIDS.2023; 34(10): 710.     CrossRef
  • Differential Impact of Degree of Hypertension on Subclinical Coronary Atherosclerosis in Asymptomatic Subjects With and Without Diabetes Mellitus
    Hyun Woo Park, Sangyong Jo, Kyung Sun Park, Hyeji Lee, Young-Jee Jeon, Sangwoo Park, Soe Hee Ann, Yong-Giun Kim, Seong Hoon Choi, Woon Jung Kwon, Young-Rak Cho, Jon Suh, Gyung-Min Park
    The American Journal of Cardiology.2023; 203: 343.     CrossRef
  • Exosomal MALAT1 Derived from High Glucose-Treated Macrophages Up-Regulates Resistin Expression via miR-150-5p Downregulation
    Kou-Gi Shyu, Bao-Wei Wang, Wei-Jen Fang, Chun-Ming Pan, Chiu-Mei Lin
    International Journal of Molecular Sciences.2022; 23(3): 1095.     CrossRef
  • Comparison of Framingham risk score and pooled cohort equations for the prediction of coronary atherosclerosis in patients who meet the target LDL-C level of Korean dyslipidemia guideline
    Su Bin Kim, Hae Won Jung
    Medicine.2022; 101(47): e31816.     CrossRef
  • Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study
    Kyoung Jin Kim, Jimi Choi, Jae Hyun Bae, Kyeong Jin Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim, Nam Hoon Kim
    Diabetes & Metabolism Journal.2021; 45(3): 368.     CrossRef
  • Frequency and Significance of Right Bundle Branch Block and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals
    Hyeji Lee, Young-Jee Jeon, Byung Ju Kang, Tae Young Lee, Eun Ji Park, Sangwoo Park, Soe Hee Ann, Yong-Giun Kim, Yongjik Lee, Seong Hoon Choi, Gyung-Min Park
    The American Journal of Cardiology.2021; 158: 30.     CrossRef
  • The association between glucose-related variables and plaque morphology in patients with ST-segment elevated myocardial infarction
    Jinxin Liu, Shanjie Wang, Can Cui, Hengxuan Cai, Rong Sun, Weili Pan, Shaohong Fang, Bo Yu
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Choosing Antithrombotic Therapy in Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus: How to Reduce the Risk of Death
    N. A. Koziolova, P. G. Karavaev, A. S. Veklich
    Kardiologiia.2020; 60(4): 109.     CrossRef
Short Communication
Clinical Diabetes & Therapeutics
A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor
You-Cheol Hwang, Jae Hyeon Kim, Byung-Wan Lee, Woo Je Lee
Diabetes Metab J. 2019;43(6):898-905.   Published online June 14, 2019
DOI: https://doi.org/10.4093/dmj.2018.0257
  • 3,868 View
  • 80 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   

We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM). We especially focused on urinary glucose excretion (UGE). This was a single-arm multicenter prospective study. A total of 92 people with T2DM aged 20 to 70 years with glycosylated hemoglobin (HbA1c) levels ≥7.0% and ≤9.5% were enrolled. Ipragliflozin (50 mg) was added to the background therapy for these people for 12 weeks. After 3 months treatment with ipragliflozin, the mean HbA1c levels were decreased from 7.6% to 6.9% and 62.0% of the people reached the HbA1c target of less than 7.0% (P<0.001). In addition, body weight, blood pressure, and lipid parameters were improved after ipragliflozin treatment (all P<0.001). The baseline HbA1c (r=0.66, P<0.001) and morning spot urine glucose to creatinine ratio (r=−0.30, P=0.001) were independently associated with the HbA1c reduction. Ipragliflozin treatment for 12 weeks improves glycemic control and other metabolic parameters. A higher HbA1c and lower UGE at baseline predicts a better glucose-lowering efficacy of ipragliflozin.

Citations

Citations to this article as recorded by  
  • Preventing and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 2 Diabetes: Promising Therapeutic Agents and Strategies
    Allison Zhang, Rita El Hachem, Jennifer Goldman
    ADCES in Practice.2024; 12(1): 38.     CrossRef
  • Association of common variant rs9934336 of SLC5A2 (SGLT2) gene with SARS-CoV-2 infection and mortality
    Anamika Das, Gunanidhi Dhangadamajhi
    Egyptian Journal of Medical Human Genetics.2024;[Epub]     CrossRef
  • β-hydroxybutyrate as a biomarker of β-cell function in new-onset type 2 diabetes and its association with treatment response at 6 months
    Minyoung Lee, Yongin Cho, Yong-ho Lee, Eun Seok Kang, Bong-soo Cha, Byung-Wan Lee
    Diabetes & Metabolism.2023; 49(4): 101427.     CrossRef
  • A Comparative Study on the Efficacy and Safety of Dose Escalation of Luseogliflozin in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control
    Tadashi Arao, Yosuke Okada, Akira Kurozumi, Yoshiya Tanaka
    Cureus.2023;[Epub]     CrossRef
  • Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitors response
    Bo Xu, Shaoqian Li, Bo Kang, Shangzhi Fan, Canyu Chen, Weiyi Li, Jixiang Chen, Zunbo He, Fan Tang, Jiecan Zhou
    Molecular Biology Reports.2023; 50(11): 9637.     CrossRef
  • Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level
    Sjoukje van der Hoek, Jasper Stevens
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitus
    Keisuke Monobe, Shinsuke Noso, Naru Babaya, Yoshihisa Hiromine, Yasunori Taketomo, Fumimaru Niwano, Sawa Yoshida, Sara Yasutake, Tatsuro Minohara, Yumiko Kawabata, Hiroshi Ikegami
    Journal of Diabetes Investigation.2021; 12(5): 728.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
Original Article
Clinical Diabetes & Therapeutics
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials
Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck
Diabetes Metab J. 2019;43(4):410-421.   Published online December 27, 2018
DOI: https://doi.org/10.4093/dmj.2018.0070
  • 6,207 View
  • 136 Download
  • 18 Web of Science
  • 18 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Based on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs on major adverse cardiovascular events (MACEs) and to identify subpopulations exhibiting the greatest cardiovascular (CV) benefit.

Methods

Three CVOTs reporting effects of long-acting GLP-1 RAs were included: LEADER (liraglutide), SUSTAIN-6 (semaglutide), and EXSCEL (exenatide once weekly). In all studies, the primary endpoint was three-point MACE, comprising CV death, non-fatal myocardial infarction, and non-fatal stroke. Overall effect estimates were calculated as hazard ratios and 95% confidence intervals (CIs) using the random-effects model; subgroup analyses reported in the original studies were similarly analyzed.

Results

Overall, statistically significant risk reductions in MACE and CV death were observed. Subgroup analysis indicated a significant racial difference with respect to CV benefit (P for interaction <0.001), and more substantial risk reductions were observed in subjects of African origin (relative risk [RR], 0.78; 95% CI, 0.60 to 0.99) and in Asians (RR, 0.35; 95% CI, 0.09 to 1.32). However, post hoc analysis (Bonferroni method) revealed that only Asians exhibited a significantly greater CV benefit from treatment, compared with white subjects (P<0.0001).

Conclusion

Long-acting GLP-1 RAs reduced risks of MACE and CV deaths in high-risk patients with type 2 diabetes mellitus. Our findings of a particularly effective reduction in CV events with GLP-1 RA in Asian populations merits further exploration and dedicated trials in specific populations.

Citations

Citations to this article as recorded by  
  • Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials,
    Frederick Berro Rivera, Nathan Ross B. Bantayan, John Paul Aparece, Linnaeus Louisse A. Cruz, John Vincent Magallong, Polyn Luz Pine, Anne Mira Nicca Idian-Javier, Grace Nooriza O. Lumbang, Edgar V. Lerma, Kyla M. Lara-Breitinger, Martha Gulati, Krishnasw
    Journal of Clinical Lipidology.2024;[Epub]     CrossRef
  • Coronary Artery Disease in South Asian Patients: Cardiovascular Risk Factors, Pathogenesis and Treatments
    Vincenzo Sucato, Giuseppe Coppola, Girolamo Manno, Giuseppe Vadalà, Giuseppina Novo, Egle Corrado, Alfredo Ruggero Galassi
    Current Problems in Cardiology.2023; 48(8): 101228.     CrossRef
  • Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
    Hodaka Yamada, Masashi Yoshida, Shunsuke Funazaki, Jun Morimoto, Shiori Tonezawa, Asuka Takahashi, Shuichi Nagashima, Kimura Masahiko, Otsuka Kiyoshi, Kazuo Hara
    Journal of Cardiovascular Development and Disease.2023; 10(4): 176.     CrossRef
  • Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus
    L. Yu. Khamnueva, L. S. Andreeva
    Problems of Endocrinology.2023; 69(2): 38.     CrossRef
  • Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
    Sian A. Bradley, Kevin J. Spring, Roy G. Beran, Dimitrios Chatzis, Murray C. Killingsworth, Sonu M. M. Bhaskar
    Diabetes/Metabolism Research and Reviews.2022;[Epub]     CrossRef
  • Obesity Pillars Roundtable: Obesity and East Asians
    Harold Edward Bays, Jennifer Ng, Jeffrey Sicat, Michelle Look
    Obesity Pillars.2022; 2: 100011.     CrossRef
  • Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
    Calvin Ke, K. M. Venkat Narayan, Juliana C. N. Chan, Prabhat Jha, Baiju R. Shah
    Nature Reviews Endocrinology.2022; 18(7): 413.     CrossRef
  • Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Timothy M. E. Davis, Anna Giczewska, Yuliya Lokhnygina, Robert J. Mentz, Naveed Sattar, Rury R. Holman
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
    Xiaoling Cai, Linong Ji
    Diabetes Therapy.2021; 12(7): 1861.     CrossRef
  • Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Jae-Seung Yun, Seung-Hyun Ko
    Metabolism.2021; 123: 154838.     CrossRef
  • Sex and ethnic differences in the cardiovascular complications of type 2 diabetes
    Jian L. Yeo, Emer M. Brady, Gerry P. McCann, Gaurav S. Gulsin
    Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110342.     CrossRef
  • Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Efficacy and safety of dulaglutide in type 2 diabetes patients in endocrinology clinics of Islamabad, Pakistan
    Matiullah Kamin, SajjadAli Khan, UmarYousaf Raja, Osama Ishtiaq, Asmara Malik, Tejhmal Rehman, MuhammadUmar Wahab
    Indian Journal of Endocrinology and Metabolism.2021; 25(5): 456.     CrossRef
  • Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in South Asians: a Unique Population with a Growing Challenge
    Afreen I. Shariff, Nitya Kumar, William S. Yancy, Leonor Corsino
    Current Diabetes Reports.2020;[Epub]     CrossRef
  • Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
    Christopher S. Wilcox
    Hypertension.2020; 75(4): 894.     CrossRef
  • Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Liyun He, Na Yang, Lingling Xu, Fan Ping, Wei Li, Yuxiu Li, Huabing Zhang
    Diabetes Therapy.2020; 11(9): 2121.     CrossRef
  • 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu, Kuan-Cheng Chang, Kou-Gi Shyu, Jin-Long Huang, Cheng-Dao Tsai, Huei-Fong Hung, Ming-En Liu, Tze-Fan Chao,
    Journal of the Chinese Medical Association.2020; 83(7): 587.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
Reviews
Pathophysiology
Role of NO/VASP Signaling Pathway against Obesity-Related Inflammation and Insulin Resistance
Yu Mi Kang, Francis Kim, Woo Je Lee
Diabetes Metab J. 2017;41(2):89-95.   Published online November 15, 2016
DOI: https://doi.org/10.4093/dmj.2017.41.2.89
  • 4,408 View
  • 59 Download
  • 20 Web of Science
  • 19 Crossref
AbstractAbstract PDFPubReader   

Obesity has quickly become a worldwide pandemic, causing major adverse health outcomes such as dyslipidemia, type 2 diabetes mellitus, cardiovascular disease and cancers. Obesity-induced insulin resistance is the key for developing these metabolic disorders, and investigation to understand the molecular mechanisms involved has been vibrant for the past few decades. Of these, low-grade chronic inflammation is suggested as a critical concept in the development of obesity-induced insulin resistance, and the anti-inflammatory effect of nitric oxide (NO) signaling has been reported to be linked to improvement of insulin resistance in multiple organs involved in glucose metabolism. Recently, a body of evidence suggested that vasodilatory-stimulated phosphoprotein (VASP), a downstream mediator of NO signaling plays a crucial role in the anti-inflammatory effect and improvement of peripheral insulin resistance. These preclinical studies suggest that NO/VASP signaling could be an ideal therapeutic target in the treatment of obesity-related metabolic dysfunction. In this review, we introduce studies that investigated the protective role of NO/VASP signaling against obesity-related inflammation and insulin resistance in various tissues.

Citations

Citations to this article as recorded by  
  • Hippocampal proteomic changes in high-fat diet-induced obese mice associated with memory decline
    Ping Lu, Cun-Xiu Gao, Fei-Jian Luo, Yu-Ting Huang, Mei-Mei Gao, Yue-Sheng Long
    The Journal of Nutritional Biochemistry.2024; 125: 109554.     CrossRef
  • Leptina, obesidad y enfermedades cardiovasculares
    Jorly Mejia-Montilla , Nadia Reyna-Villasmil, Andreina Fernández-Ramírez, Eduardo Reyna-Villasmil
    Revista Repertorio de Medicina y Cirugía.2023; 32(3): 218.     CrossRef
  • Urinary and circulatory netrin-1 as biomarker in diabetes and its related complications: a systematic review and meta-analysis
    Amir Hossein Behnoush, Amirmohammad Khalaji, Zahra Shokri Varniab, Afshin Rahbarghazi, Elahe Amini, Aleksandra Klisic
    Endocrine.2023;[Epub]     CrossRef
  • Impact of ultraviolet radiation on cardiovascular and metabolic disorders: The role of nitric oxide and vitamin D
    Qing‐Ling Quan, Kyeong‐No Yoon, Ji Su Lee, Eun Ju Kim, Dong Hun Lee
    Photodermatology, Photoimmunology & Photomedicine.2023; 39(6): 573.     CrossRef
  • Beneficial Metabolic Effects of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in a Mouse Diet-Induced Obesity Model
    Chad D. Schwartzkopf, John R. Hadcock, Guang Liu, Peter Germano, Julien Roux, Courtney M. Shea, Emmanuel S. Buys, Juli E. Jones
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway
    Hui Ye, Yanan He, Chuan Zheng, Fang Wang, Ming Yang, Junzhi Lin, Runchun Xu, Dingkun Zhang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study
    Min-Kyung Lee, Jae-Hyuk Lee, Seo-Young Sohn, Seo Yeon Lee, Tae-Yoong Jeong, Sae Chul Kim
    Diabetology & Metabolic Syndrome.2022;[Epub]     CrossRef
  • In situ hydrogel capturing nitric oxide microbubbles accelerates the healing of diabetic foot
    Yingzheng Zhao, Lanzi Luo, Lantian Huang, Yingying Zhang, Mengqi Tong, Hanxiao Pan, Jianxun Shangguan, Qing Yao, Shihao Xu, Helin Xu
    Journal of Controlled Release.2022; 350: 93.     CrossRef
  • Amelioration effect of black seed oil against high‐fat diet‐induced obesity in rats through Nrf2/HO‐1 pathway
    Nada F. Abo El‐Magd, Mohamed El‐Mesery, Amro El‐Karef, Mamdouh M. El‐Shishtawy
    Journal of Food Biochemistry.2021;[Epub]     CrossRef
  • An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension
    John P. Hanrahan, Jelena P. Seferovic, James D. Wakefield, Phebe J. Wilson, Jennifer G. Chickering, Joon Jung, Kenneth E. Carlson, Daniel P. Zimmer, Andrew L. Frelinger, Alan D. Michelson, Linda Morrow, Michael Hall, Mark G. Currie, G. Todd Milne, Albert
    Diabetologia.2020; 63(4): 733.     CrossRef
  • Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue
    Cristina Antinozzi, Paolo Sgrò, Luigi Di Luigi
    International Journal of Endocrinology.2020; 2020: 1.     CrossRef
  • Association of endothelial dysfunction with incident prediabetes, type 2 diabetes and related traits: the KORA F4/FF4 study
    Marie-Theres Huemer, Cornelia Huth, Florian Schederecker, Stefanie J Klug, Christa Meisinger, Wolfgang Koenig, Wolfgang Rathmann, Annette Peters, Barbara Thorand
    BMJ Open Diabetes Research & Care.2020; 8(1): e001321.     CrossRef
  • Embelin from Embelia ribes ameliorates oxidative stress and inflammation in high-fat diet-fed obese C57BL/6 mice
    Priyanka Bansal, Uma Bhandari, Sayeed Ahmad
    Pharmacognosy Magazine.2020; 16(5): 443.     CrossRef
  • Weight change is significantly associated with risk of thyroid cancer: A nationwide population-based cohort study
    Hyemi Kwon, Kyung-Do Han, Cheol-Young Park
    Scientific Reports.2019;[Epub]     CrossRef
  • Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
    Sunghwan Suh, Kwang-Won Kim
    Diabetes & Metabolism Journal.2019; 43(6): 733.     CrossRef
  • Antioxidant, antihyperglycemic, and antidiabetic activity of Apis mellifera bee tea
    Janielle da Silva Melo da Cunha, Tamaeh Monteiro Alfredo, Jéssica Maurino dos Santos, Valter Vieira Alves Junior, Luiza Antas Rabelo, Emerson Silva Lima, Ana Paula de Araújo Boleti, Carlos Alexandre Carollo, Edson Lucas dos Santos, Kely de Picoli Souza, M
    PLOS ONE.2018; 13(6): e0197071.     CrossRef
  • Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes
    Jisook Yim, Gyuri Kim, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jeong-Ho Kim, Jin Won Cho, Sang-Guk Lee, Yong-ho Lee
    Frontiers in Endocrinology.2018;[Epub]     CrossRef
  • Glycyrrhizin ameliorates high fat diet-induced obesity in rats by activating NrF2 pathway
    Nada F. Abo El-Magd, Mohamed El-Mesery, Amro El-Karef, Mamdouh M. El-Shishtawy
    Life Sciences.2018; 193: 159.     CrossRef
  • cGMP-dependent protein kinase I (cGKI) modulates human hepatic stellate cell activation
    Andras Franko, Marketa Kovarova, Susanne Feil, Robert Feil, Robert Wagner, Martin Heni, Alfred Königsrainer, Marc Ruoß, Andreas K. Nüssler, Cora Weigert, Hans-Ulrich Häring, Stefan Z. Lutz, Andreas Peter
    Metabolism.2018; 88: 22.     CrossRef
Clinical Care/Education
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
Sung-Ho Kim, Jung-Hwa Yoo, Woo Je Lee, Cheol-Young Park
Diabetes Metab J. 2016;40(5):339-353.   Published online September 12, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.5.339
  • 6,309 View
  • 160 Download
  • 42 Web of Science
  • 40 Crossref
AbstractAbstract PDFPubReader   

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease glucagon secretion, and contribute to reducing postprandial hyperglycemia. Although DPP-4 inhibitors have similar benefits, they can be differentiated in terms of their chemical structure, pharmacology, efficacy and safety profiles, and clinical considerations. Gemigliptin (brand name: Zemiglo), developed by LG Life Sciences, is a potent, selective, competitive, and long acting DPP-4 inhibitor. Various studies have shown that gemigliptin is an optimized DPP-4 inhibitor in terms of efficacy, safety, and patient compliance for treatment of type 2 diabetes mellitus. In this review, we summarize the characteristics of gemigliptin and discuss its potential benefits in clinical practice.

Citations

Citations to this article as recorded by  
  • A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inh
    Hae Jin Kim, Jung Hyun Noh, Min Kyong Moon, Sung Hee Choi, Seung-Hyun Ko, Eun-Jung Rhee, Kyu Yeon Hur, In-Kyung Jeong, Mark Yorek
    Journal of Diabetes Research.2024; 2024: 1.     CrossRef
  • Gemigliptin, a potent selective dipeptidyl peptidase 4 inhibitor, protects endothelial progenitor cells by oxidative stress via caspase-3 dependent pathway
    Mijung Lee, Amna Rashid Tariq, Manho Kim
    Biochemistry and Biophysics Reports.2024; 38: 101673.     CrossRef
  • Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression
    Du Hyun Ro, Gun Hee Cho, Ji Yoon Kim, Seong Ki Min, Ha Ru Yang, Hee Jung Park, Sun Young Wang, You Jung Kim, Myung Chul Lee, Hyun Cheol Bae, Hyuk‐Soo Han
    Aging Cell.2024;[Epub]     CrossRef
  • Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
    Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang, Jincheng Wang
    Acta Pharmaceutica Sinica B.2023; 13(6): 2383.     CrossRef
  • Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study
    Sang-Yong Kim, Sungrae Kim
    Diabetes Therapy.2023; 14(1): 109.     CrossRef
  • Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium–glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults
    Sae Im Jeong, Yun Kim, Jae Jin Nah, Wan Huh, In‐Jin Jang, Jun Gi Hwang, SeungHwan Lee
    British Journal of Clinical Pharmacology.2023; 89(6): 1780.     CrossRef
  • 1,2,3‐Triazole analogs with bulky and conformationally rigid substructures: Synthesis and in vitro evaluation as DPP‐4 inhibitors
    Duy‐Viet Vo, Jongkook Lee, Haeil Park
    Bulletin of the Korean Chemical Society.2023; 44(5): 425.     CrossRef
  • DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
    Kunika Saini, Smriti Sharma, Yousuf Khan
    Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
  • The effect of gemigliptin treatment on immune parameters including regulatory T cells in patients with type 2 diabetes and moderate to very severe chronic renal impairment
    Yanghyeon Kim, Nagyeom Lee, Sujung Heo, Ye Na Kim, Ho Sik Shin, Yeonsoon Jung, Hark Rim
    Medicine.2023; 102(49): e36455.     CrossRef
  • Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
    Sangmo Hong, Chang Hee Jung, Song Han, Cheol-Young Park
    Diabetes & Metabolism Journal.2022; 46(1): 63.     CrossRef
  • Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
    Petr Busek, Jonathan S. Duke-Cohan, Aleksi Sedo
    Cancers.2022; 14(9): 2072.     CrossRef
  • Divergent Reaction of Activated Pyridines with α,α-Difluorinated gem-Diols: Regioselective Synthesis of gem-Difluorinated Dihydropyridines and Dihydropyridones
    Koushik Patra, Mallu Kesava Reddy, Sumitava Mallik, Mahiuddin Baidya
    Organic Letters.2022; 24(22): 4014.     CrossRef
  • Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
    Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung
    Biochemical and Biophysical Research Communications.2022; 626: 135.     CrossRef
  • FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years
    Aathira Sujathan Nair, Ashutosh Kumar Singh, Astik Kumar, Sunil Kumar, Sunitha Sukumaran, Vishal Payyalot Koyiparambath, Leena K. Pappachen, T. M. Rangarajan, Hoon Kim, Bijo Mathew
    Processes.2022; 10(10): 2054.     CrossRef
  • Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
    Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, Nigel H. Greig
    Pharmacological Research.2022; 186: 106550.     CrossRef
  • An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004–2018)
    Mahanjit Konwar, MiteshR Maurya, TusharB Nishandar, UrmilaM Thatte, NithyaJ Gogtay
    Perspectives in Clinical Research.2021; 12(3): 159.     CrossRef
  • Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
    Eunsol Yang, Hyounggyoon Yoo, In-Jin Jang, Kyung-Sang Yu, SeungHwan Lee
    Drug Design, Development and Therapy.2021; Volume 15: 651.     CrossRef
  • Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
    Deep Dutta, Anshita Agarwal, Indira Maisnam, Rajiv Singla, Deepak Khandelwal, Meha Sharma
    Endocrinology and Metabolism.2021; 36(2): 374.     CrossRef
  • Structure–Activity Relationship Analysis of Cocrystallized Gliptin-like Pyrrolidine, Trifluorophenyl, and Pyrimidine-2,4-Dione Dipeptidyl Peptidase-4 Inhibitors
    Katarina Tomovic, Budimir S. Ilic, Andrija Smelcerovic
    Journal of Medicinal Chemistry.2021; 64(14): 9639.     CrossRef
  • A review upon medicinal perspective and designing rationale of DPP-4 inhibitors
    Shubham Kumar, Anu Mittal, Amit Mittal
    Bioorganic & Medicinal Chemistry.2021; 46: 116354.     CrossRef
  • Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial
    Thananda Trakarnvanich, Bancha Satirapoj, Swangjit Suraamornkul, Thanit Chirananthavat, Anoma Sanpatchayapong, Torpong Claimon, Eusebio Chiefari
    Journal of Diabetes Research.2021; 2021: 1.     CrossRef
  • Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system
    Hojin Oh, Hai Duc Nguyen, In Mo Yoon, Byung-Ryong Ahn, Min-Sun Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
    Seon Mee Kang, Jeong Hyun Park
    Clinical Medicine Insights: Endocrinology and Diabetes.2021; 14: 117955142110516.     CrossRef
  • The vasodilatory effect of gemigliptin via activation of voltage-dependent K+ channels and SERCA pumps in aortic smooth muscle
    Hee Seok Jung, Mi Seon Seo, Jin Ryeol An, Minji Kang, Ryeon Heo, Hongliang Li, Won-Kyo Jung, Il-Whan Choi, Eun-Hee Cho, Hongzoo Park, Young Min Bae, Won Sun Park
    European Journal of Pharmacology.2020; 882: 173243.     CrossRef
  • Development and Validation of a Rapid and Sensitive Method for the Simultaneous Estimation of Gemigliptin and Teneligliptin in Bulk and Dosage Forms by Using Liquid Chromatography-tandem Mass Spectrometry
    Amrish Chandra, Ramji Rathod, Faraat Ali, Anuj Prakash, Robin Kumar, Gyanendra Nath Singh
    Current Pharmaceutical Analysis.2020; 16(8): 1104.     CrossRef
  • Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
    Elliot J. Glotfelty, Thomas E. Delgado, Luis B. Tovar-y-Romo, Yu Luo, Barry J. Hoffer, Lars Olson, Tobias E. Karlsson, Mark P. Mattson, Brandon K. Harvey, David Tweedie, Yazhou Li, Nigel H. Greig
    ACS Pharmacology & Translational Science.2019; 2(2): 66.     CrossRef
  • Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection
    Katarina Tomovic, Jelena Lazarevic, Gordana Kocic, Marina Deljanin‐Ilic, Marko Anderluh, Andrija Smelcerovic
    Medicinal Research Reviews.2019; 39(1): 404.     CrossRef
  • Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
    Yoo-Ri Chung, Kyoung Hwa Ha, Hyeon Chang Kim, Sang Jun Park, Kihwang Lee, Dae Jung Kim
    Diabetes & Metabolism Journal.2019; 43(5): 640.     CrossRef
  • Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models
    Dae-Hwan Nam, Jinsook Park, Sun-Hyun Park, Ki-Suk Kim, Eun Bok Baek
    The Korean Journal of Physiology & Pharmacology.2019; 23(5): 329.     CrossRef
  • Clinical Use of DPP-4 Inhibitors
    Baptist Gallwitz
    Frontiers in Endocrinology.2019;[Epub]     CrossRef
  • Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report
    Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyoungmin Kim, Kwan Woo Lee
    Diabetes Therapy.2019; 10(4): 1271.     CrossRef
  • Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus
    Jaehyun Bae, Youjin Kim, Yongin Cho, Minyoung Lee, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Bong-Soo Cha, Dong Jin Joo, Kyu Ha Huh, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
    Transplantation Proceedings.2019; 51(10): 3444.     CrossRef
  • Protective effects of gemigliptin against type II collagen degradation in human chondrocytes
    Momin Mohetaer, Guoqing Li, Yang Wang, Li Cao
    Biomedicine & Pharmacotherapy.2018; 104: 590.     CrossRef
  • Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers
    Ignacio Conde-Carmona, Sandra García-Medina, Juan M. Jiménez-Vargas, Alberto Martínez-Muñoz, Sung-Hack Lee
    Clinical Therapeutics.2018; 40(10): 1729.     CrossRef
  • Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40‐week extension of the GUARD randomized study
    Sang Youb Han, Sun Ae Yoon, Byoung Geun Han, Sung Gyun Kim, Young‐Il Jo, Kyung Hwan Jeong, Kook‐Hwan Oh, Hyeong Cheon Park, Sun‐Hee Park, Shin‐Wook Kang, Ki‐Ryang Na, Sun Woo Kang, Nam‐Ho Kim, Younghwan Jang, Bogyeong Kim, Seonghye Shin, Dae Ryong Cha
    Diabetes, Obesity and Metabolism.2018; 20(2): 292.     CrossRef
  • Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
    Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, Jinhee Lee, Hansol Choi, Hyeon Chang Kim, Dae Jung Kim
    Korean Circulation Journal.2018; 48(5): 395.     CrossRef
  • Gemigliptin: Newer promising gliptin for type 2 diabetes mellitus
    Manish Gutch, Abhay Joshi, Sukriti Kumar, Avinash Agarwal, RajendraKumar Pahan, SyedMohd Razi
    Indian Journal of Endocrinology and Metabolism.2017; 21(6): 898.     CrossRef
  • Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
    Seung Hee Choi, Jaechan Leem, In-Kyu Lee
    Mediators of Inflammation.2017; 2017: 1.     CrossRef
  • Effects of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, on lipid metabolism and endotoxemia after a high‐fat meal in patients with type 2 diabetes
    Chang Ho Ahn, Eun Ky Kim, Se Hee Min, Tae Jung Oh, Young Min Cho
    Diabetes, Obesity and Metabolism.2017; 19(3): 457.     CrossRef
  • Efficacy and safety of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24‐week, multicentre, randomized, double‐blind, placebo‐
    Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, Joo Young Nam, Kyu Jeung Ahn, Tae Keun Oh, Hyoung Woo Lee, Dae Ho Lee, Jaetaek Kim, Choon Hee Chung, Tae Sun Park, Byung Joon Kim, Seok Won Park, Hyeong Kyu Park, Kwang Jae Lee, Sang‐Wook Kim, Jeong Hyun Park, Kwa
    Diabetes, Obesity and Metabolism.2017; 19(5): 635.     CrossRef
Original Articles
Complications
Serum Total Bilirubin Levels Provide Additive Risk Information over the Framingham Risk Score for Identifying Asymptomatic Diabetic Patients at Higher Risk for Coronary Artery Stenosis
Jaechan Leem, Eun Hee Koh, Jung Eun Jang, Chang-Yun Woo, Jin Sun Oh, Min Jung Lee, Joon-Won Kang, Tae-Hwan Lim, Chang Hee Jung, Woo Je Lee, Joong-Yeol Park, Ki-Up Lee
Diabetes Metab J. 2015;39(5):414-423.   Published online October 22, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.5.414
  • 4,186 View
  • 30 Download
  • 7 Web of Science
  • 7 Crossref
AbstractAbstract PDFPubReader   
Background

The diagnosis of coronary artery disease (CAD) is often delayed in patients with type 2 diabetes. Serum total bilirubin levels are inversely associated with CAD. However, no studies have examined whether this can be used as a biochemical marker for identifying asymptomatic diabetic patients at higher risk for having obstructive CAD.

Methods

We performed a cross-sectional study of 460 consecutive asymptomatic patients with type 2 diabetes. All patients underwent coronary computed tomographic angiography, and their serum total bilirubin levels were measured. Obstructive CAD was defined as ≥50% diameter stenosis in at least one coronary artery.

Results

Serum total bilirubin tertiles showed an inverse association with the prevalence of obstructive CAD. In multivariate logistic regression analysis, the odds ratio for the highest versus the lowest tertile of total bilirubin was 0.227 (95% confidence interval [CI], 0.130 to 0.398), and an increment of 1 µmol/L in serum total bilirubin level was associated with a 14.6% decrease in obstructive CAD after adjustment for confounding variables. Receiver operating characteristic curve analysis showed that the area under the curve for the Framingham Risk Score (FRS) plus serum total bilirubin level was 0.712 (95% CI, 0.668 to 0.753), which is significantly greater than that of the FRS alone (P=0.0028).

Conclusion

Serum total bilirubin level is inversely associated with obstructive CAD and provides additive risk information over the FRS. Serum total bilirubin may be helpful for identifying asymptomatic patients with type 2 diabetes who are at higher risk for obstructive CAD.

Citations

Citations to this article as recorded by  
  • DECREASE IN SERUM BILIRUBIN AS AN UNFAVORABLE MARKER OF CARDIOVASCULAR DISORDERS
    L. M. Strilchuk, O. O. Zimba, I. B. Zhakun
    Eastern Ukrainian Medical Journal.2020; 8(3): 268.     CrossRef
  • Contemporary diagnostic algorithm for coronary artery disease: achievements and prospects
    A. S. Akselrod, D. Yu. Shchekochikhin, E. S. Tebenkova, A. V. Zhelankin, D. A. Stonogina, E. A. Syrkina, S. K. Ternovoy
    Kardiologiya i serdechno-sosudistaya khirurgiya.2019; 12(5): 418.     CrossRef
  • Pharmacological actions and therapeutic potentials of bilirubin in islet transplantation for the treatment of diabetes
    Qing Yao, Xue Jiang, Longfa Kou, Adelaide T. Samuriwo, He-Lin Xu, Ying-Zheng Zhao
    Pharmacological Research.2019; 145: 104256.     CrossRef
  • Evaluation of genetic effect of NOS3 and G×E interaction on the variability of serum bilirubin in a Han Chinese population
    Yingshui Yao, Zhengmei Fang, Song Yang, Hailong Zhao, Yanchun Chen, Yuelong Jin, Xianghai Zhao, Lijun Zhu, Yuanrui Tian, Chong Shen
    Nitric Oxide.2017; 70: 25.     CrossRef
  • Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin—Potential for Preventing or Slowing the Progression of Diabetic Complications
    Mark McCarty
    Healthcare.2017; 5(1): 15.     CrossRef
  • Effect of bilirubin concentration on the risk of diabetic complications: A meta-analysis of epidemiologic studies
    Bo Zhu, Xiaomei Wu, Yifei Bi, Yang Yang
    Scientific Reports.2017;[Epub]     CrossRef
  • Role of Bilirubin in Diabetic Vascular Complications: Can Bilirubin Predict More than Just Liver Disease?
    Jun Sung Moon
    Diabetes & Metabolism Journal.2015; 39(5): 384.     CrossRef
Serum Ceruloplasmin Level as a Predictor for the Progression of Diabetic Nephropathy in Korean Men with Type 2 Diabetes Mellitus
Min Jung Lee, Chang Hee Jung, Yu Mi Kang, Jung Eun Jang, Jaechan Leem, Joong-Yeol Park, Woo Je Lee
Diabetes Metab J. 2015;39(3):230-239.   Published online April 22, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.3.230
  • 4,339 View
  • 46 Download
  • 22 Web of Science
  • 22 Crossref
AbstractAbstract PDFPubReader   
Background

Oxidative stress is known to be associated with progression of diabetic kidney disease. Ceruloplasmin acts as a pro-oxidant under conditions of severe oxidative stress. Thus, we conducted a longitudinal observational study to evaluate whether the serum ceruloplasmin level is a predictive biomarker for progression of diabetic nephropathy.

Methods

A total of 643 Korean men with type 2 diabetes mellitus were enrolled. Serum ceruloplasmin was measured using a nephelometric method. Progression of diabetic nephropathy was defined as transition in albuminuria class (i.e., normoalbuminuria to microalbuminuria, microalbuminuria to macroalbuminuria, or normoalbuminuria to macroalbuminuria) and/or a greater than 2-fold increase of serum creatinine at follow-up compared with the baseline value.

Results

During the follow-up period (median, 2.7 years; range, 0.3 to 4.4 years), 49 of 643 patients (7.6%) showed the progression of diabetic nephropathy and three patients (0.5%) developed end-stage renal disease. Baseline ceruloplasmin levels were higher in the progressors than in the nonprogressors (262.6±40.9 mg/L vs. 233.3±37.8 mg/L, P<0.001). Kaplan-Meier analysis showed a significantly higher incidence of nephropathy progression according to ceruloplasmin tertile (log-rank test, P<0.001). The hazard ratio (HR) for progression of diabetic nephropathy was significantly higher in the highest ceruloplasmin tertile category compared with the lowest ceruloplasmin tertile category, even after adjusting for confounding variables (HR, 3.32; 95% confidence interval, 1.28 to 8.61; P=0.003).

Conclusion

Baseline serum ceruloplasmin is an independent predictive factor for the progression of diabetic nephropathy in patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by  
  • In-depth urinary and exosome proteome profiling analysis identifies novel biomarkers for diabetic kidney disease
    Shichun Du, Linhui Zhai, Shu Ye, Le Wang, Muyin Liu, Minjia Tan
    Science China Life Sciences.2023; 66(11): 2587.     CrossRef
  • Serum Level of Ceruloplasmin, Angiotensin-Converting Enzyme and Transferrin as Markers of Severity in SARS-CoV-2 Infection in Patients with Type 2 Diabetes
    Patricia-Andrada Reștea, Ștefan Țigan, Laura Grațiela Vicaș, Luminița Fritea, Eleonora Marian, Tunde Jurca, Annamaria Pallag, Iulius Liviu Mureșan, Corina Moisa, Otilia Micle, Mariana Eugenia Mureșan
    Microbiology Research.2023; 14(4): 1670.     CrossRef
  • The nephropathy of sickle cell trait and sickle cell disease
    Kenneth I. Ataga, Santosh L. Saraf, Vimal K. Derebail
    Nature Reviews Nephrology.2022; 18(6): 361.     CrossRef
  • Integrated Analysis of Single-Cell RNA-seq and Bulk RNA-seq in the Identification of a Novel ceRNA Network and Key Biomarkers in Diabetic Kidney Disease
    Yuejun Wang, Mingming Zhao, Yu Zhang
    International Journal of General Medicine.2022; Volume 15: 1985.     CrossRef
  • Molecular Functions of Ceruloplasmin in Metabolic Disease Pathology
    Zhidong Liu, Miao Wang, Chunbo Zhang, Shigao Zhou, Guang Ji
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 695.     CrossRef
  • A correlative study of copper, ceruloplasmin, iron, total iron binding capacity and total antioxidant capacity in diabetic nephropathy
    Ramlingareddy, Shivashankara A Ramachandrayya, Jeena Jacob, Malathi Mala
    Biomedicine.2022; 42(3): 469.     CrossRef
  • Novel biomarkers for prognosticating diabetic kidney disease progression
    Shilna Muttickal Swaminathan, Indu Ramachandra Rao, Srinivas Vinayak Shenoy, Attur Ravindra Prabhu, Pooja Basthi Mohan, Dharshan Rangaswamy, Mohan V Bhojaraja, Shivashankara Kaniyoor Nagri, Shankar Prasad Nagaraju
    International Urology and Nephrology.2022; 55(4): 913.     CrossRef
  • Evaluation of Serum Ceruloplasmin Levels as a Biomarker for Oxidative Stress in Patients With Diabetic Retinopathy
    Gurunadh Satyanarayana, Narendra Keisham, Hitender S Batra, Subrahmanya Murti V, Mansur Khan, Sandeep Gupta, Vikram Mahindra
    Cureus.2021;[Epub]     CrossRef
  • Prospection of plasma proteins as biomarkers for diabetes mellitus monitoring
    Liliane de Paula Silva, Fabiane Gomes de Moraes Rego, Geraldo Picheth, Marcelo Müller-Santos, Dayane Alberton
    Journal of Diabetes & Metabolic Disorders.2021; 20(1): 611.     CrossRef
  • Risk assessment for foot ulcers among Tunisian subjects with diabetes: a cross sectional outpatient study
    B. Zantour, S. Bouchareb, Z. El Ati, F. Boubaker, W. Alaya, W. Kossomtini, M. H. Sfar
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • Metalloproteins and apolipoprotein C: candidate plasma biomarkers of T2DM screened by comparative proteomics and lipidomics in ZDF rats
    Shuai Wang, Zhiyuan Lu, Yuxin Wang, Tianran Zhang, Xiaodong He
    Nutrition & Metabolism.2020;[Epub]     CrossRef
  • Emerging vistas on electrochemical detection of diabetic retinopathy biomarkers
    K.S. Shalini Devi, Madhurantakam Sasya, Uma Maheswari Krishnan
    TrAC Trends in Analytical Chemistry.2020; 125: 115838.     CrossRef
  • Oxidative stress in peritoneal dialysis patients: Association with the dialysis adequacy and technique survival
    Natalia Stepanova, Lesya Korol, Olena Burdeyna
    Indian Journal of Nephrology.2019; 29(5): 309.     CrossRef
  • Recent advancements in biopolymer and metal nanoparticle-based materials in diabetic wound healing management
    Veena Vijayakumar, Sushanta K. Samal, Smita Mohanty, Sanjay K. Nayak
    International Journal of Biological Macromolecules.2019; 122: 137.     CrossRef
  • Rat Böbrek Dokusunda Kurşunun Neden Olduğu Oksidatif Strese Karşı Kitosanın Koruyucu etkisi
    Ugur ÖZDEK, Hasan TOZ, Ahmet Ufuk KÖMÜROĞLU, Leyla MİS, Zübeyir HUYUT, Yeter DEĞER
    Van Veterinary Journal.2019; 30(3): 187.     CrossRef
  • Changes in Trace Elements During Early Stages of Chronic Kidney Disease in Type 2 Diabetic Patients
    Ching-Chiang Lin, Ching-Tang Shih, Chien-Hung Lee, Yeou-Lih Huang
    Biological Trace Element Research.2018; 186(2): 330.     CrossRef
  • The Divalent Elements Changes in Early Stages of Chronic Kidney Disease
    Wan-Ju Kung, Ching-Tang Shih, Chien-Hung Lee, Ching-Chiang Lin
    Biological Trace Element Research.2018; 185(1): 30.     CrossRef
  • Long-term expression of glomerular genes in diabetic nephropathy
    Dominik Chittka, Bernhard Banas, Laura Lennartz, Franz Josef Putz, Kathrin Eidenschink, Sebastian Beck, Thomas Stempfl, Christoph Moehle, Simone Reichelt-Wurm, Miriam C Banas
    Nephrology Dialysis Transplantation.2018;[Epub]     CrossRef
  • Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies
    D. N. Koye, J. E. Shaw, C. M. Reid, R. C. Atkins, A. T. Reutens, D. J. Magliano
    Diabetic Medicine.2017; 34(7): 887.     CrossRef
  • Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis
    Pengzi Zhang, Jing Lu, Yali Jing, Sunyinyan Tang, Dalong Zhu, Yan Bi
    Annals of Medicine.2017; 49(2): 106.     CrossRef
  • Biomarkers of diabetic nephropathy: A 2017 update
    Nektaria Papadopoulou-Marketou, Christina Kanaka-Gantenbein, Nikolaos Marketos, George P. Chrousos, Ioannis Papassotiriou
    Critical Reviews in Clinical Laboratory Sciences.2017; 54(5): 326.     CrossRef
  • Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes
    Hung-Yuan Li, Hung-An Lin, Feng-Jung Nien, Vin-Cent Wu, Yi-Der Jiang, Tien-Jyun Chang, Hsien-Li Kao, Mao-Shin Lin, Jung-Nan Wei, Cheng-Hsin Lin, Shyang-Rong Shih, Chi-Sheng Hung, Lee-Ming Chuang, Emmanuel A Burdmann
    PLOS ONE.2016; 11(2): e0147981.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal